The sickle cell disease treatment market size was estimated to be US$ 900 million in 2021 and is projected to accelerate at a CAGR of 12% through 2032.
As of now, 22 to 27 million individuals overall are apparently living with sickle cell disease and around 317,000 newborn children are conceived every year with the disease.
The worldwide market for sickle cell disease treatment has been extending close by developing requirement for treating diseases concerned with blood plasma and similar factors. As of now, accessible treatments for sickle cell disease give suggestive assistance and alleviative care. Albeit bone marrow transplant is the lone healing treatment for SCD, patients aged above 16 years are for the most part the only ones to go through this treatment as dangers related with Bone Marrow Transplant in grown-ups are high.
Clinical experts suggest quick treatment systems for patients whose hemoglobin levels are low. The current treatment for persistent SCD essentially comprises hydroxyurea and blood transfusions. For the most part, an enormous number of patients foster bigotry to hydroxyurea.
Patients getting blood transfusions are in danger of iron surcharge, blood-borne infections, fever, and unfavorably susceptible responses from various organs. Around 20% of patients experiencing sickle cell disease are transfusion dependent. The absence of repayment is relied upon to go about as an obstruction to the development of the disease treatment.
The tough FDA endorsement measure for sickle cell disease drug endorsement is expected to thwart the development of the market during the forecast period of 2023-2032. This factor is projected to speed up the development of the worldwide sickle cell disease treatment market in the years to come. The worldwide sickle cell disease treatment market is expected to draw in financing from new sectors during the forecast period of 2023-2032.
Global Sickle Cell Disease Treatment Market Value Share Analysis, by Geography (2022)
The report titled “Global Sickle Cell Disease Treatment Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032”, wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the Global Sickle Cell Disease Treatment Market.
Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.
The global Sickle Cell Disease Treatment market is segmented based on Treatment Indication, and region. Based on Treatement indication, the Sickle Cell Disease Treatment market is segmented into Sickle cell anemia, Sickle beta thalassemia, Others. Based on geography, the Global Sickle Cell Disease Treatment Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada, and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Italy, France, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.
The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on Global Sickle Cell Disease Treatment Market. Further, market share of prominent companies in the Global Sickle Cell Disease Treatment Market would also be estimated.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the Sickle Cell Disease Treatment companies. The Global Sickle Cell Disease Treatment Market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution.
Product portfolio would focus on all the products under the Sickle Cell Disease Treatment business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the Global Sickle Cell Disease Treatment Market.
The key players of the Global Sickle Cell Disease Treatment Market are Novartis AG, Pfizer Inc., bluebird bio, Inc., Global Blood Therapeutics, Inc., GlycoMimetics, Inc., F. Hoffmann-La Roche AG, Emmaus Life Sciences, Inc., Bristol-Myers Squibb, CRISPR Therapeutics, and others.
Global Sickle Cell Disease Treatment Market Key Segments:
Based on Treatment Indication
By Region
The sickle Cell Disease Treatment market was worth US$ 900 million in 2021.
The global market for sickle Cell Disease Treatment will most likely expand at over 12% CAGR through 2032.
Some key players operating in the sickle Cell Disease Treatment market include Novartis AG, Pfizer Inc., bluebird bio, Inc., Global Blood Therapeutics, Inc., GlycoMimetics, Inc., F. Hoffmann-La Roche AG, Emmaus Life Sciences, Inc., Bristol-Myers Squibb, CRISPR Therapeutics.
The base year considered in sickle Cell Disease Treatment market report is 2022.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved